Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
The present invention concerns methods and compositions for treatment of HIV infection in a subject, utilizing a DNL® complex comprising at least one anti-HIV therapeutic agent, attached to an antibody, antibody fragment or PEG. In a preferred embodiment, the antibody or fragment binds to an antigen selected from gp120, gp41, CD4 and CCR5. In a more preferred embodiment the antibody is P4/D10 or 2G12, although other anti-HIV antibodies are known and may be utilized. In a most preferred embodiment, the anti-HIV therapeutic agent is a fusion inhibitor, such as T20, T61, T651, T1249, T2635, CP32M or T-1444, although other anti-HIV therapeutic agents are known and may be utilized. The DNL® complex may be administered alone or may be co-administered with one or more additional anti-HIV therapeutic agents.
IBC Pharmaceuticals, Inc.
C A A C A C A A A C A C C C A A C A A A C A
C07K A61K A61K C07K A61K C07K A61K A61K A61P C07K A61K C07K C07K C07K A61K A61K C07K A61K A61K A61K C07K A61K
additional inventional inventional additional inventional additional inventional inventional inventional additional inventional additional inventional additional inventional additional additional inventional inventional inventional inventional inventional
Chien-Hsing David M.
Chang Goldenberg